Industry & Policy News

[Arrowhead Pharmaceuticals, Inc.] Arrowhead Pharmaceuticals, Inc. announced that it has gained rights to ARO-PNPLA3, formerly called JNJ-75220795, which was part of a 2018 research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

[GSK plc] GSK plc announced that the US FDA Oncologic Drugs Advisory Committee voted 8 to 5 in support of the question whether data from two proposed single-arm trials will be “sufficient to characterize the benefits and risks” of Jemperli in the curative-intent setting for patients with mismatch repair-deficient/microsatellite instability-high locally advanced rectal cancer.

[Baylor College of Medicine] Baylor College of Medicine has been awarded more than $5.8 million in grants by the Cancer Prevention & Research Institute of Texas (CPRIT) to support innovative translational research and cancer treatments.

[University of Prince Edward Island] Miranda Steeves, a Master of Science student at the University of Prince Edward Island (UPEI), is working on breast cancer research, with assistance from the Beatrice Hunter Cancer Research Institute and $11,900 in funding provided by the Canadian Cancer Society’s J.D. Irving, Limited—Excellence in Cancer Research Fund.

[RadioMedix, Inc. (Globe Newswire)] RadioMedix, Inc. announced the acquisition of its 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals. RadioMedix will provide manufacturing support to Fusion for the TATCIST trial and the first pivotal clinical trial to evaluate the safety and efficacy of 225Ac-PSMA-I&T for metastatic castration-resistant prostate cancer.

[The University of Texas MD Anderson Cancer Center] The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere™ technology in support of preclinical research to accelerate the development of novel cancer therapies.